|
gptkbp:instanceOf
|
antidepressant
selective serotonin reuptake inhibitor
|
|
gptkbp:approvedBy
|
1989
|
|
gptkbp:ATCCode
|
N06AB04
|
|
gptkbp:blackBoxWarning
|
suicidality in children, adolescents, and young adults
|
|
gptkbp:brand
|
gptkb:Celexa
|
|
gptkbp:CASNumber
|
59729-33-8
|
|
gptkbp:category
|
gptkb:drug
|
|
gptkbp:chemicalFormula
|
racemic mixture
C20H21FN2O
|
|
gptkbp:contraindication
|
QT prolongation
concurrent use with MAOIs
|
|
gptkbp:discoveredBy
|
gptkb:Lundbeck
|
|
gptkbp:drugClass
|
SSRI
|
|
gptkbp:eliminationHalfLife
|
35 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:FDAApproved
|
yes
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:hasEnantiomer
|
gptkb:escitalopram
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
citalopram
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:maximumDose
|
40 mg/day
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:metabolism
|
gptkb:desmethylcitalopram
gptkb:didesmethylcitalopram
liver
|
|
gptkbp:metabolizingEnzyme
|
gptkb:CYP2C19
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
324.4 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
80%
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young people)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
insomnia
dry mouth
sexual dysfunction
somnolence
increased sweating
|
|
gptkbp:synonym
|
gptkb:Cipramil
gptkb:Seropram
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
anxiety disorders
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|